Arbutus Biopharma Corporation (GB:0SGC)

Arbutus Biopharma (0SGC) Stock Price & Analysis


0SGC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.90 - $3.14
Previous Close$2.49
Average Volume (3M)3.10K
Market Cap
Enterprise Value$270.72M
Total Cash (Recent Filing)$146.73M
Total Debt (Recent Filing)$2.12M
Price to Earnings (P/E)N/A
Aug 03, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares OutstandingN/A
10 Day Avg. Volume1,498
30 Day Avg. Volume3,100
Standard DeviationN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.47
Enterprise Value/Gross Profit6.94
Enterprise Value/Ebitda-3.89
Price Target Upside114.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4




What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $1.90 and its highest was $3.14 in the past 12 months.
    What is Arbutus Biopharma Corporation’s market cap?
    Currently, no data Available
    When is Arbutus Biopharma Corporation’s upcoming earnings report date?
    Arbutus Biopharma Corporation’s upcoming earnings report date is Aug 03, 2023 which is in 67 days.
      How were Arbutus Biopharma Corporation’s earnings last quarter?
      Arbutus Biopharma Corporation released its earnings results on May 04, 2023. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.036.
        Is Arbutus Biopharma Corporation overvalued?
        According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Arbutus Biopharma Corporation pay dividends?
          Arbutus Biopharma Corporation does not currently pay dividends.
          What is Arbutus Biopharma Corporation’s EPS estimate?
          Arbutus Biopharma Corporation’s EPS estimate is -$0.11.
            How many shares outstanding does Arbutus Biopharma Corporation have?
            Currently, no data Available
            What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
            Arbutus Biopharma Corporation reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
              Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is Woodline Partners LP. It holds Arbutus Biopharma Corporation’s shares valued at 8M.


                Arbutus Biopharma Stock Smart Score

                The Arbutus Biopharma Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Arbutus Biopharma Corporation

                Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Scholar Rock Holding
                Lexicon Pharmaceuticals
                C4 Therapeutics
                Poseida Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis